Suvretta Capital Management »

89bio shares owned by Suvretta Capital Management

Quarter-by-quarter ownership of 89bio (ETNB) shares owned by Suvretta Capital Management from 13F filings

Historical chart of Suvretta Capital Management investment in 89bio

Tip: Access up to 7 years of quarterly data

All positions including 89bio held by Suvretta Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 89bio by Suvretta Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $42M 2.7M 15.44
2023-06-30 $45M 2.4M 18.95
2023-03-31 $34M 2.2M 15.23

More positions owned by Suvretta Capital Management

Royalty Pharma Shs Class A (RPRX)
Biohaven (BHVN)
Arcellx Common Stock (ACLX)
Horizon Therapeutics Pub L SHS
Insmed Com Par $.01 (INSM)
Meta Platforms Cl A (META)
Amazon (AMZN)
Advanced Micro Devices (AMD)
Intra Cellular Therapies (ITCI)
Microsoft Corporation (MSFT)
Kura Oncology (KURA)
Wynn Resorts (WYNN)
Marinus Pharmaceuticals Com New (MRNS)
89bio (ETNB)
General Electric Com New (GE)

View all positions for Suvretta Capital Management

Top funds holding 89bio

RA Capital Management
Henderson Group
Vanguard Group
BVF
Holocene Advisors
Laurion Capital Management
Citadel Advisors
Frazier Life Sciences Management
Redmile Group
Federated Investors
Westfield Capital Management Company
Superstring Capital Management
Franklin Resources
Orchard Capital Managment
Caption Management

View all funds holding 89bio